anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide an X-ray contrast medium containing barium sulfate and L-sorbose, and having improved composite functions. CONSTITUTION:The objective X-ray contrast medium contains 1 pt.wt. of barium sulfate and 0.01-1.0pt.wt. of L-sorbose. The tendency of the precipitation and aggregation of barium sulfate paticles in aqueous suspension because of its high density can be mitigated by the surfactant activity of L-sorbose, and accordingly, a contrast medium having high dispersion stability can be prepared. It is takable easily without necessitating the administration of a cathartic after the examination to prevent the constipation. It can be applied even to the patient of diabetes. It is storable in powdery form without causing the aggregation by moisture absorption and is free from contamination with microorganism even in fluid state.
Complete Atrioventricular Block 

  


Patients who receive octreotide acetate injection intravenously may be at increased risk for higher degree atrioventricular blocks. In postmarketing reports, complete atrioventricular block was reported in patients receiving IV octreotide acetate injection during surgical procedures. In the majority of patients, octreotide acetate injection was given at higher than recommended doses and/or as a continuous IV infusion. The safety of continuous IV infusion has not been established in patients receiving octreotide acetate injection for the approved indications. Consider cardiac monitoring in patients receiving octreotide acetate injection intravenously.

  


Other Cardiac Conduction Abnormalities

  


Other cardiac conduction abnormalities have occurred during treatment with octreotide acetate injection. In acromegalic patients, bradycardia (< 50 bpm) developed in 25%; conduction abnormalities occurred in 10% and arrhythmias occurred in 9% of patients during octreotide acetate injection therapy [see Adverse Reactions (6)]. Other electrocardiogram (ECG) changes observed included QT prolongation, axis shifts, early repolarization, low voltage, R/S transition, and early R-wave progression. These ECG changes are not uncommon in acromegalic patients. Dose adjustments in drugs such as beta-blockers that have bradycardia effects may be necessary. In one acromegalic patient with severe congestive heart failure (CHF), initiation of octreotide acetate injection therapy resulted in worsening of CHF with improvement when drug was discontinued. Confirmation of a drug effect was obtained with a positive rechallenge.
High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
PURPOSE:To obtain a pharmaceutical containing a physiologically active polypeptide for oral administration or administration into the oral cavity by blending a polypeptide with an absorbefacient composed of a combination of an organic acid with a sucrose ester of a fatty acid. CONSTITUTION:A pharmaceutical is obtained by blending a physiologically active polypeptide (e.g. calcitonin) with an organic acid (e.g. malic acid or succinic acid) and a sucrose ester of a fatty acid (e.g. sucrose stearate) in combination as an absorbefacient. In a pharmaceutical for oral administration, 0.1-70wt.% organic acid and 0.1-50wt.% sucrose ester of the fatty acid are blended. In a pharmaceutical for administration into the oral cavity (a sublingual tablet), 0.1-30wt.% organic acid and 0.1-20wt.% sucrose ester of the fatty acid are blended. Since polypeptide hormones undergo hydrolysis by a proteolytic enzyme and not sufficiently absorbed and desired pharmacological action is not exhibited, high absorption of the hardly absorbable polypeptide hormones from intestinal tracts or mucous membranes in the oral cavity is obtained by blending the absorbefacient.
PURPOSE: A study effect improvement device for ubiquitous-learning based on a study emotion index generated from situational information and a body emotion index is provided to recommend proper contents to a user based on the study emotion index received from a middleware device. CONSTITUTION: A student emotion acknowledgement module(210) generates a body emotion index related to a brain state of a user from a body signal of the user. A learning environment acknowledgement module(230) generates state information for a surrounding situation of the user. A standard index database(290) stores standard index data showing a relationship between the body emotion index and a study emotion index obtained from an performed experiment with a plurality of users. A middleware module(250) generates the study emotion index based on the body emotion index, the study emotion index, and situation information. [Reference numerals] (210) Student emotion acknowledgement module; (230) Learning environment acknowledge module; (250) Middleware module; (290) Standard learning emotion/state index data; (AA) Learning adapter; (BB) U-learning device; (CC) Emotion/state index analyzing process; (DD) Generation of learning emotion/state indexes; (EE) Sensing of emotion/state changes; (FF) Standard learning emotion index data; (GG) Standard learning state index data
Colon diverticulosis (CD) is extremely common and the prevalence seems to increase globally. The prevalence of CD increases with age and two-thirds of the adult population eventually develop CD. In the US the prevalence of CD was 32.6 % in patients aged 50-59 years and 71.4% in patients \> 80 years of age. CD is often detected incidentally during optical colonoscopy (OC) or by computer tomography (CT). In approximately 25 % of patients with CD symptomatic colon diverticular disease develop typically comprising bloating, abdominal pain and change in bowel habits. Progression to diverticulitis is estimated to appear in approximately 1%. Most patients present with uncomplicated diverticulitis and are managed by general practitioners (GP) with the use of painkillers and oral antibiotics. Complicated diverticulitis due to perforation can be classified according to Hinchey et al. as a guidance to surgeon as to how conservative they can be. Hinchey level 1-2 can be managed conservatively. In the case of Hinchey level 3 and 4 it requires a laparoscopy with peritoneal lavage or laparotomy with colon resection and stoma formation, respectively. In patients presenting at the GP with intractable pain or signs of sepsis admission to hospital services is mandatory. Upon hospitalization, CT is the preferred diagnostic imaging modality in patients presenting with abdominal pain and suspected diverticulitis. If colonic diverticulitis is described as the symptoms-eliciting pathology without complications comprising abscess or bowel perforation patients are typically discharged from hospital with painkillers and offered an OC within 4-6 weeks, when the inflammation has resolved, to confirm the diverticulitis diagnosis. Routine OC after an episode of diverticulitis is recommended by the majority of international guidelines including Danish guidelines on handling of patients with diverticulitis. Due to a very low risk of malignancy in patients with diverticulitis the relevance of routine OC has been questioned in a recent review. The research in Colon Capsule Endoscopy (CCE) has evolved substantially since the introduction in 2006. More studies have reported a diagnostic yield equal to OC also in regard to larger polyps \> 9 mm. In contrast to OC, CCE does not offer the possibility of biopsy or removal polyp. Hence, the ideal population for CCE needs to have low risk of findings with the need of endoscopic intervention. CCE is without pain and the risk of complications is extremely low compared to colonoscopy for which the estimated risk of major bleeding or perforation is 12 per 10,000 patients.

The investigators aimed to evaluate the effect of introducing CCE on patient satisfaction and discomfort compared to colonoscopy as a follow-up examination in patients with diverticulitis and the impact of introducing CCE on the need for subsequent colonoscopy.
The invention discloses smoked plum containing compound granules with a summer-heat dispelling function and a preparation method of the smoked plum containing compound granules. The smoked plum containing compound granules is prepared from raw materials in pars by weight as follows: 500-580 parts of honeysuckle stems, 60-90 parts of smoked plum, 65-90 parts of hawthorn fruits, 600-650 parts of saccharose, 60-80 parts of dextrin, 3-4.5 parts of citric acid and 1-2 parts of dementholized peppermint oil. The preparation method of the smoked plum containing compound granules with the summer-heat dispelling function comprises material preparation, boiling, concentration, spray granulation and aftertreatment. The granules have efficacy of heat clearing and summer-heat dispelling. Some parameters in a preparation process of the smoked plum containing compound granules with the summer-heat dispelling function are perfected further, the effective utilization rate of drugs is increased, the greater efficacy of the granules can be exerted, and meanwhile, the effect and the efficiency of the smoked plum containing compound granules with the summer-heat dispelling function are improved. The preparation method of the smoked plum containing compound granules with the summer-heat dispelling function is simple to operate, convenient to prepare, low in cost and suitable for large-scale industrial production.
Pill of Aframomum melegueta extract 50 mg with Food grade Maltodextrin 12 . Once daily for three days.
BACKGROUND: Acute myeloid leukaemia (AML) is a haematological malignancy with unfavourable prognosis. Despite the effectiveness of chemotherapy and targeted therapy, relapse or drug resistance remains a major threat to AML patients. N6-methyladenosine (m6A) RNA methylation and super-enhancers (SEs) are extensively involved in the leukaemogenesis of AML. However, the potential relationship between m6A and SEs in AML has not been elaborated.
METHODS: Chromatin immunoprecipitation (ChIP) sequencing data from Gene Expression Omnibus (GEO) cohort were analysed to search SE-related genes. The mechanisms of m6 A-binding proteins IGF2BP2 and IGF2BP3 on DDX21 were explored via methylated RNA immunoprecipitation (MeRIP) assays, RNA immunoprecipitation (RIP) assays and luciferase reporter assays. Then we elucidated the roles of DDX21 in AML through functional assays in vitro and in vivo. Finally, co-immunoprecipitation (Co-IP) assays, RNA sequencing and ChIP assays were performed to investigate the downstream mechanisms of DDX21.
RESULTS: We identified two SE-associated transcripts IGF2BP2 and IGF2BP3 in AML. High enrichment of H3K27ac, H3K4me1 and BRD4 was observed in IGF2BP2 and IGF2BP3, whose expression were driven by SE machinery. Then IGF2BP2 and IGF2BP3 enhanced the stability of DDX21 mRNA in an m6A-dependent manner. DDX21 was highly expressed in AML patients, which indicated a poor survival. Functionally, knockdown of DDX21 inhibited cell proliferation, promoted cell apoptosis and led to cell cycle arrest. Mechanistically, DDX21 recruited transcription factor YBX1 to cooperatively trigger ULK1 expression. Moreover, silencing of ULK1 could reverse the promoting effects of DDX21 overexpression in AML cells.
CONCLUSIONS: Dysregulation of SE-IGF2BP2/IGF2BP3-DDX21 axis facilitated the progression of AML. Our findings provide new insights into the link between SEs and m6A modification, elucidate the regulatory mechanisms of IGF2BP2 and IGF2BP3 on DDX21, and reveal the underlying roles of DDX21 in AML.
FIELD: medicine. SUBSTANCE: new dentifrice water betters condition of gingivae, prevents formation of soft dental deposit, inflammation and diseases of gingivae and eliminates unpleasant scent. Dentifrice water produces pronounced curative and prophylactic effect owing to combination of vegetational extracts, natural essential oils and various wound healing and epithelizing components such as allantoin derivative of procaine. Dentifrice water contains extracts of oak bark, clove, eucalyptus, one of the daisy, calendula, St. John's wort or sage extracts, one of the extracts of dog rose or mountain ash or dill seeds, one of the extracts of sweet flag root, coriander or caraway seeds. Dentifrice water further includes grapefruit, lemon, orange, mint, and anise oils as aromatizers taken in amount of 1 : 2 : 2.6 : 5.3 : 3.3. Moreover, new dentifrice water includes procaine mandelate or procaine hydrochloride as procaine derivative. EFFECT: noticeable curative and prophylactic effect. 2 cl, 5 tbl
FIELD: medicine, pharmacy, pharmaceutical technology. SUBSTANCE: pharmaceutical composition has an effective amount of haloperidol as an active component and the following special additions, mas. pts. /1 mas. pts. of haloperidol: lactose, 41.1-57.0; starch, 8.2-12.5; aerosil, 1.0-2.0; talc, 0.2-2.0; stearate, 0.2-0.9. To prepare the composition haloperidol taken in effective amount in mixture with lactose, starch and aerosil is wetted with 3% starch glue paste. Mixture is passed through granulator, wetted granulate is dried, dried granules are passed through granulator, powdered with a mixture of starch with talc and stearate and tabletted. Invention can be used for treatment of patients with psychotic diseases and vomiting of different genesis. Development of new tabletted form of haloperidol corresponds to all requirements of State Pharmacopoeia of XI Edition. EFFECT: higher efficiency. 8 cl, 1 tbl
INTRODUCTION: Postoperative sleep disturbances significantly impair postoperative recovery. The administration of intravenous esketamine has been shown to potentially improve postoperative sleep quality. However, the effectiveness of epidural esketamine in improving postoperative sleep quality remains to be elucidated. This study aims to explore the impact of both intraoperative and postoperative use of epidural esketamine on the postoperative sleep quality of patients undergoing minimally invasive lower abdominal surgeries.
METHODS AND ANALYSIS: This randomised, double-blind, parallel-group, placebo-controlled trial will be conducted at the Fudan University Shanghai Cancer Centre. A total of 128 adults undergoing minimally invasive lower abdominal surgeries will be randomly allocated in a 1:1 ratio to either the esketamine group or the placebo group. In the esketamine group, epidural esketamine will be administered intraoperatively (0.2 mg/kg) and postoperatively (25 mg). Postoperatively, all patients will receive epidural analgesia. The primary outcome of the study is the incidence of poor sleep quality on the third day after surgery. The sleep quality assessment will be conducted using the Pittsburgh Sleep Quality Index and a Numeric Rating Scale of sleep. The main secondary outcomes include postoperative pain and anxiety and depression scores. The postoperative pain, both rest pain and movement pain, will be assessed using a Numerical Rating Scale within 5 days after surgery. Anxiety and depression scores will be evaluated using the Hospital Anxiety and Depression Scale both before and after the surgery. Safety outcomes will include delirium, fidgeting, hallucinations, dizziness and nightmares. The analyses will be performed in accordance with intention-to-treat principle ETHICS AND DISSEMINATION: Ethics approval has been obtained from the Ethics Committee of the Shanghai Cancer Centre (2309281-9). Prior to participation, all patients will provide written informed consent. The results of the trial are intended to be published in a peer-reviewed journal.
TRIAL REGISTRATION NUMBER: ChiCTR2300076862.
Patients diagnosed with epicondylitis in our outpatient clinic will be divided into 3 groups, and patients who will receive saline in 1 group and betamethasone sodium in a group will be selected in accordance with the specified conditions and their treatment will be started, and the treatment will be started, which patient will receive which treatment will be determined by the computerized randomization program. ), 1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), 1 ml saline (0.9 NACI), while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day.Examination and functional scores to be applied to the patients during follow-up: VAS, DASH and PRTEE scores will be checked in the 1st 6th week, 3rd month, 6th month and 12th month VAS: Visual Analog Scale DASH: The Disabilities of the Arm, Shoulder and Hand PRTEE: The Patient-Rated Tennis Elbow Evaluation 2. It will be evaluated by USG in the 3rd month.
A medical monitoring device, operating system, and method is provided for managing administration of medical treatment regimens for treating a patient's medical conditions. The device stores medication schedule data, treatment data, patient query data, and patient response data. The device includes a controller for controlling modes of operation of the device, controlling access of the memory, controlling display of the treatment data and the patient query data on a display, receiving and processing patient response data, tracking timing, and providing scheduled medication alarm signals. The device further includes dedicated keys interfaced with the controller. Each dedicated key is associated with one of the medical treatment regimens, and initiates the display of treatment messages relating to the associated medical treatment regimen. Successive actuation of each dedicated key initiates the display of further treatment messages relating to the associated medical treatment regimen. The device further includes soft function keys interfaced with the controller. The soft function keys signal the controller, commanding it to execute different modes of operation of the medical monitoring device. The device provides scheduled medication alarm signals that alert the user concerning prescribed medications due to be taken.
Theophylline may be stabilized in aqueous solution by the interaction of theophylline, an amino acid and an alkali metal hydroxide.  The theophylline may be dissolved in the aqueous alkali metal hydroxide and the amino acid added thereto, or alternatively, aqueous solutions of the alkali metal salts of theophylline or the amino acid may be used in conjunction with the appropriate free amino acid or theophylline as may be. Glycine, alanine, valine, leucine and glutamic acid are the specified amino acids and potassium and sodium the alkali metals.ALSO:Theophyllin compositions stable in aqueous solutions are prepared by mixing together in aqueous solution theophylline and an aliphatic amino acid under conditions such that one of the aforementioned substances is in the form of its alkali metal salt. The theophylline may be dissolved in aqueous alkali metal hydroxide and the amino acid added thereto, or, alternatively, aqueous solutions of alkali metal salts of theophylline or the amino acid may be used in conjunction with the appropriate free amino acid or theophylline, as may be.  The aqueous solution so formed may be used as such or evaporated to dryness to form a solid composition. The composition may also include a basic aluminium salt of an amino acid.  Glycine, alanine, valine, leucine and glutamic acid are specified amino acids, while potassium and sodium hydroxides are specified alkali metal hydroxides.
The utility model relates to medicamentous form, in particular of capsules, which include, in wt. units: silimarin 0.060-0.080, lactose monohydrate 0.0525-0.0725, magnesium stearate 0.0020-0.0040, talcum 0.0035-0.0055, povidon 0.0050-0.0070, highly dispersed silicon dioxide 0.0030-0.0050, ethyl alcohol 95% and water. The product is produced by mixing of the initial raw materials and granulation of the powder mixture with aqueous ethanol solution of povidon, which improves the rheologic properties of the granule and ensures the necessary informity of the mass. After drying, granule mass is produced which can easily be filled in capsules. For improving the property of running of the granule mass, the substitution of starch and microcrystalline cellulose with lactose is also a contribution. The medicamentous form has guaranteed effect of the active substance and stability during all its shelf life.
A small cyclic peptide is provided having high affinity for the platelet GP IIbIIIa receptor, which peptide is represented by formula .alpha. where R1 and R4 are from 0 to 4 amino acids, R3 is from 1 to 4 amino acids; R2 is -CH2CO- or from 1 to 4 amino acids; Xaa8 may be Met, Phe, nLeu, Ile, Asp, Lys, Arg and Gln; and Z is a linking group, either disulfide, thioether or amide, but preferably disulfide. Preferred cyclic peptides exhibiting high inhibition potency in a platelet aggregation assay are represented by formula .beta. where Xaa2, Xaa3 and Xaa4 may be any amino acid but preferably are Arg, Ile and Pro, respectively.  Xaa8 is preferably Met, Phe or nLeu; Xaa10 when present, is preferably Ala; and Xaa11, when present, is preferably Ala or Asp. These compounds may be effectively employed in a pharmaceutical composition containing a pharmaceutically acceptable excipient for reducing platelet aggregation in a mammal. The pharmaceutical composition is especially useful in treating a mammal having an increased propensity for thrombus formation, and may be used in combination with an anticoagulant or thrombolytic agent.
PURPOSE:To uniformize, reinforce, and enhance the effect of chemical treatment of keratin fiber, by irradiating ultrasonic waves on the keratin fiber. CONSTITUTION:There are two cases in the chemical treatment of keratin fiber: one is the case where it is carried out by immersing the keratin fiber in a liquid, and the other is the case where it is carried out by applying a liquid on the keratin fiber. In the former case, ultrasonic waves are oscillated in the liquid so as to be propagated through the liquid and are irradiated on the keratin fiber. In the latter case, ultrasonic waves may be oscillated in the air so as to be irradiated on the keratin fiber through propagation in the air, or ultrasonic waves may be oscillated in the liquid so as to be irradiated on the keratin fiber through propagation in the air. In the case where a keratin fiber is subjected to ultrasonic treatment, the frequency of the ultrasonic waves of 25kHz or more will be sufficient. When a ultrasonic cleaning device is used, the intensity of the ultrasonic waves suitable for the clearing purpose will be sufficient. Thus, the keratin fiber is hardly impaired, and the chemical treatment of keratin fiber can be reinforced and enhanced.